Sep 13, 2022 / 02:00PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
Good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Really pleased to have Moderna with us. Quickly before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.
So really pleased to have Stephen Hoge, who is the President of Moderna with us.
Questions and Answers:
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive DirectorStephen, I thought a good place to start off is, before we go into details about the many programs that you have ongoing, everybody obviously knows the company because of COVID. And as I think about the stock, right, there's a decent amount of debate still on what the COVID tail looks like. But I think when you think about the company,
Trustpilot
